Ahead of today’s opening bell, Thursday morning Weekly Jobless Claims are out, and they continue to portray a labor market cruising along at a healthy low rate of unemployment claims. Initial Jobless Claims came in at an even +200K, 8K below expectations and a tick up from the slightly upwardly revised +199K the previous week. Our trailing four-week average on new jobless claims is now +202K, -15K lower per week than the previous four weeks.Continuing Claims, reported a week in arrears from new claims, reac ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Thursday.The Dow traded up 0.78% to 49,462.35 while the NASDAQ gained 0.94% to 23,443.19. The S&P 500 also rose, gaining, 0.63% to 6,918.78.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsCommunication services shares gained by 1.3% on Thursday.In trading on Wednesday, utilities stocks dipped by 0.5%.Top HeadlineAbbott Laboratories (NYSE ...

Labor Market - Initial Jobless Claims came in at +200K, which is 8K below expectations and a slight increase from the previous week's revised figure of +199K [1] - The four-week average of new jobless claims is now +202K, which is -15K lower than the previous four weeks [1] Continuing Claims - Continuing Claims reached 1.85 million, down from 1.884 million reported a week ago, marking the second-lowest tally since the previous high of 1.9+ million claims [2] Economic Growth - Q3 GDP was revised up by 10 basis points to +4.4%, the highest single quarter since +4.7% in Q3 of 2023, driven by increases in exports, investments, and inventories [3] Earnings Reports - GE Aerospace reported Q4 earnings of $1.57 per share, beating estimates of $1.44, with revenues of $11.87 billion, a +5.38% surprise, but shares are down -3% due to slowing revenue growth [4] - Procter & Gamble's fiscal Q2 earnings were $1.88, slightly above estimates, while revenues were $22.21 billion, falling short by -0.36% [5] - Abbott Labs met earnings estimates at $1.50 per share but fell short of revenue projections at $11.46 billion, leading to a -7.2% drop in shares [6] - Freeport-McMoRan reported earnings of 47 cents per share, exceeding the estimated 28 cents, with revenues of $5.63 billion, surpassing expectations of $5.18 billion [7] Upcoming Earnings - Major companies such as Intel, Intuitive Surgical, and Capital One are set to release earnings after today's close, all currently holding Zacks Rank 3 (Hold) ratings [8]

Core Insights - Abbott Laboratories reported fourth-quarter 2025 adjusted EPS of $1.50, aligning with estimates and showing an 11.9% increase from the previous year [1] - Full-year 2025 adjusted EPS was $5.15, reflecting a 10.3% year-over-year growth [1] - The company’s fourth-quarter revenues were $11.46 billion, a 4.4% increase year-over-year, but missed estimates by 2.8% [2] Financial Performance - The GAAP EPS for Q4 was $1.01, down from $5.27 in Q4 2024 [1] - Full-year 2025 worldwide sales reached $44.33 billion, up 5.7% year-over-year, but also missed estimates by 0.6% [2] - Gross profit for Q4 increased by 8.4% to $6.54 billion, with a gross margin expansion of 208 basis points to 57% [9] Segment Performance - Established Pharmaceuticals segment sales rose 9% to $1.38 billion, with organic sales growth of 7.1% [4] - Medical Devices segment sales increased 12.3% to $5.68 billion, driven by strong growth in Electrophysiology, Heart Failure, and Diabetes Care [5] - Nutrition sales declined 8.9% to $1.94 billion, with Pediatric Nutrition down 10.1% and Adult Nutrition down 8.2% [6][7] Future Guidance - For 2026, Abbott projects adjusted EPS between $5.55 and $5.80, with organic sales growth expected to be between 6.5% and 7.5% [11] - The first quarter of 2026 EPS is projected to be between $1.12 and $1.18 [11] Market Reaction - Following the earnings announcement, Abbott's stock fell 5.4% in pre-market trading [3] - The decline in Nutrition sales is attributed to lower sales volumes and strategic pricing actions [12]

雅培(ABT.US)跌超12%，最低105.79美元，创2024年7月以来新低。消息面上，雅培Q4营收为114.6亿美 元，低于分析师平均预期的118亿美元，主要是因为诊断业务因新冠检测需求急剧下降，且受到特朗普 政府冻结对外援助的影响；调整后每股收益为1.5美元，同比增长12%。雅培CEO表示，营养品业务在 2026年上半年的表现仍将面临挑战，预计将在下半年恢复增长。(格隆汇) ...

Financial Data and Key Metrics Changes - In Q4 2025, sales increased by 3.8% excluding COVID testing sales, with adjusted earnings per share (EPS) of $1.50 reflecting a growth of 12% compared to the prior year [18] - Adjusted gross margin was 57.1% of sales, an increase of 20 basis points year-over-year, while adjusted operating margin rose to 25.8%, reflecting an increase of 150 basis points [18] - The company forecasts adjusted EPS for 2026 to be in the range of $5.55-$5.80, indicating a 10% growth at the midpoint [19] Business Line Data and Key Metrics Changes - Nutrition sales declined in Q4, impacted by market share loss and increased manufacturing costs, with a focus on reigniting volume growth through price and promotion initiatives [9][10] - Diagnostics sales decreased by 3.5% due to a decline in COVID testing, while Core Lab Diagnostics grew by 3.5%, achieving accelerating growth [11] - EPD (Established Pharmaceuticals Division) saw a 7% increase in sales, with double-digit growth in India and several Latin American and Middle Eastern countries [12] - Medical devices sales grew by 10.5%, driven by a 12% increase in continuous glucose monitors and strong performance in electrophysiology and structural heart segments [12][14] Market Data and Key Metrics Changes - The U.S. pediatric nutrition business faced challenges due to market share loss and increased price sensitivity among consumers [9][10] - Core Lab Diagnostics growth was 7% excluding China, reflecting durable demand globally [11] - EPD's growth was well-balanced across markets, with significant contributions from emerging markets [12] Company Strategy and Development Direction - The company aims to transition back to a more balanced growth profile, focusing on volume growth alongside price increases [10] - The acquisition of Exact Sciences is expected to enhance Abbott's position in the cancer diagnostics market, adding a high-growth business to its portfolio [8] - The company plans to launch at least eight new products in the nutrition segment over the next 12 months to support growth [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in the nutrition business but expressed confidence in the ability to reignite volume growth and return to positive growth in the second half of 2026 [27] - The company expects continued momentum in most business segments, with a focus on innovation and operational excellence driving growth [8][29] - Management highlighted the importance of addressing price sensitivity and the need for a sustainable growth strategy in the nutrition segment [25][27] Other Important Information - The company anticipates a favorable impact from foreign exchange on full-year reported sales, estimated at around 1% [19] - The adjusted tax rate is forecasted to be in the range of 15%-16% for the year [19] Q&A Session Summary Question: Concerns about revenue growth guidance - Management acknowledged a slight reduction in top-line guidance primarily due to challenges in the nutrition business but maintained EPS guidance in line with consensus [23][24] Question: Insights on the EP product portfolio - Management emphasized the successful launch of the Vault PFA catheter and the strategic positioning of Abbott's EP portfolio, expecting to grow in line with market trends [34][39] Question: Guidance considerations and risk adjustments - Management explained that the guidance reflects a mix of stable growth in core segments and anticipated recovery in diagnostics, with a focus on maintaining high single-digit growth [42][45] Question: Continuous glucose monitor (CGM) growth expectations - Management projected continued strong growth in CGM sales, driven by market expansion opportunities and new product launches [50][56] Question: Capital allocation and M&A strategy - Management indicated a focus on integrating Exact Sciences post-acquisition, with potential for smaller tuck-in acquisitions in the future [69][70]

Financial Data and Key Metrics Changes - In Q4 2025, sales increased by 3.8% excluding COVID testing sales, with adjusted earnings per share (EPS) of $1.50 reflecting a growth of 12% compared to the prior year [18] - Adjusted gross margin was 57.1% of sales, an increase of 20 basis points year-over-year, while adjusted operating margin rose by 150 basis points to 25.8% [18] - The company forecasts adjusted EPS for 2026 to be in the range of $5.55-$5.80, indicating a 10% growth at the midpoint [19] Business Line Data and Key Metrics Changes - Nutrition sales declined in Q4, impacted by market share loss and increased manufacturing costs, with a focus on reigniting volume growth through price and promotion initiatives [9][10] - Diagnostics sales decreased by 3.5% due to a decline in COVID testing, but Core Lab Diagnostics grew by 3.5%, with a full-year growth of 7% excluding China [11] - EPD (Established Pharmaceuticals Division) saw a 7% sales increase, with double-digit growth in India and several Latin American and Middle Eastern countries [12] - Medical devices sales grew by 10.5%, driven by a 12% increase in continuous glucose monitors (CGM) and strong performance in electrophysiology and structural heart segments [12][14] Market Data and Key Metrics Changes - The U.S. pediatric nutrition business faced challenges due to a loss of a large WIC contract, leading to a need for volume growth strategies [9] - Core Lab Diagnostics experienced durable demand globally, with growth in markets outside of China [11] - EPD's growth was well-balanced across markets, with significant contributions from emerging markets [12] Company Strategy and Development Direction - The company aims to transition back to a volume-driven growth model in nutrition, with plans to launch at least eight new products in the next 12 months [10] - The acquisition of Exact Sciences is expected to enhance Abbott's position in the cancer diagnostics market, adding a high-growth business to its portfolio [8] - The company is focused on innovation and operational excellence to drive growth in 2026, with a forecast of 7% organic sales growth [8] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the nutrition segment due to price sensitivity among consumers and the need for a sustainable growth model [9][10] - The outlook for 2026 includes expectations of accelerating growth in diagnostics and continued strong performance in cardiovascular and diabetes products [29] - Management expressed confidence in the ability to navigate short-term challenges in nutrition and return to growth in the second half of the year [27] Other Important Information - The company is committed to maintaining a growing dividend and has a strong balance sheet to support future investments [70] - Management emphasized the importance of integrating Exact Sciences post-acquisition and the potential for tuck-in acquisitions in the future [70] Q&A Session Summary Question: Concerns about revenue growth guidance - Management acknowledged a slight reduction in top-line guidance primarily due to challenges in the nutrition business but maintained EPS guidance in line with consensus [23][24] Question: Insights on the electrophysiology (EP) portfolio - Management highlighted the successful launch of Volt and TactiFlex Duo products, positioning Abbott favorably in the EP market with a comprehensive portfolio [34][39] Question: Guidance considerations and risk adjustments - Management discussed the balance of sustaining growth in core segments while addressing short-term challenges in nutrition, with expectations for mid-single-digit growth in diagnostics [42][45] Question: Continuous glucose monitor (CGM) market outlook - Management expressed optimism about CGM growth, projecting continued market expansion and penetration opportunities across various patient groups [52][56] Question: Capital allocation and Exact Sciences acquisition - Management confirmed focus on integrating Exact Sciences and maintaining a strong capital allocation strategy, with no immediate changes to dilution expectations [70][72]

Financial Data and Key Metrics Changes - In Q4 2025, Abbott reported a 3.8% increase in sales when excluding COVID testing sales, with adjusted earnings per share (EPS) of $1.50 reflecting a 12% growth compared to the prior year [19] - The adjusted gross margin was 57.1% of sales, an increase of 20 basis points year-over-year, while adjusted operating margin rose to 25.8%, reflecting a 150 basis point increase [19] - For 2026, Abbott forecasts adjusted EPS in the range of $5.55-$5.80, indicating a 10% growth at the midpoint, and organic sales growth expected to be between 6.5%-7.5% [20] Business Line Data and Key Metrics Changes - Nutrition sales declined in Q4 due to market share loss and increased manufacturing costs, with a focus on reigniting volume growth through price and promotion initiatives [9][10] - Diagnostics sales decreased by 3.5% due to a decline in COVID testing, while Core Lab Diagnostics grew by 3.5%, and point-of-care diagnostics saw a 7% increase driven by a new troponin test [12] - The Established Pharmaceutical Division (EPD) experienced a 7% sales increase, with double-digit growth in India and several Latin American and Middle Eastern countries [13] - Medical devices sales grew by 10.5%, with continuous glucose monitors (CGM) sales increasing by 12% in Q4 and 17% for the year, exceeding $7.5 billion [13][14] Market Data and Key Metrics Changes - The U.S. pediatric nutrition business faced challenges due to a loss of a large WIC contract, impacting overall sales [10] - Core Lab Diagnostics growth was 7% excluding China, reflecting durable demand globally [12] - EPD's growth was well-balanced across markets, with significant contributions from high-demand therapies in emerging markets [13] Company Strategy and Development Direction - Abbott's acquisition of Exact Sciences aims to enhance its position in the cancer diagnostics market, adding a high-growth business to its portfolio [8] - The company is focusing on innovation and operational excellence, with a forecast for 2026 driven by new product launches and strategic execution [8] - Abbott plans to transition its nutrition business back to a volume-driven growth model, emphasizing innovation and product development [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the nutrition segment due to price sensitivity among consumers and rising manufacturing costs, indicating a need for strategic changes [10][26] - The outlook for 2026 is optimistic, with expectations of accelerating growth driven by a strong product pipeline and the integration of Exact Sciences [30][47] - Management expressed confidence in the ability to navigate short-term challenges in nutrition and return to positive growth in the second half of the year [28][29] Other Important Information - Abbott's investment strategy in medical devices focuses on sustaining strong performance in high-growth segments while also investing in foundational segments [15][16] - The company is committed to maintaining a growing dividend and has a strong balance sheet to support future investments [70] Q&A Session Summary Question: Concerns about revenue growth guidance - Management acknowledged a slight reduction in top-line guidance primarily due to challenges in the nutrition business but maintained EPS guidance in line with consensus [24][25] Question: Insights on the EP product portfolio - Management highlighted the successful launch of the Vault catheter and the strategic positioning of Abbott's EP portfolio, expecting to grow in line with market trends [39] Question: Outlook for diagnostics in China - Management indicated that while growth in China is expected to be stable, the U.S. and other international markets are performing well, with an overall mid-single-digit growth outlook for diagnostics [84] Question: Future of CGM growth - Management expressed optimism about CGM growth, projecting continued market expansion and penetration opportunities across various patient segments [54][58] Question: Capital allocation and M&A strategy - Management emphasized the focus on integrating Exact Sciences post-acquisition while remaining open to smaller tuck-in acquisitions [70][71]

Core Insights - Abbott Laboratories reported fourth-quarter 2025 sales of $11.46 billion, slightly below the consensus estimate of $11.80 billion, with a sales increase of 4.4% on a reported basis and 3% on an organic basis [2][10] - The company provided a first-quarter 2026 earnings outlook of $1.12-$1.18 per share, lower than the consensus of $1.20, and projected fiscal 2026 adjusted earnings of $5.55-$5.80 per share compared to Wall Street's expectation of $5.67 [10] Earnings Snapshot - Adjusted earnings for the quarter were reported at $1.50, aligning with Wall Street estimates [2] - Medical Devices segment sales increased by 12.3% on a reported basis and 10.4% on an organic basis, totaling $5.68 billion [3] Segment Performance - Sales growth in Medical Devices was driven by double-digit growth in electrophysiology, heart failure, diabetes care, and rhythm management [4] - Diabetes Care sales of continuous glucose monitors reached $2.0 billion, growing 15% [5] - Global Diagnostics sales decreased by 2.5% to $2.46 billion, with COVID-19 testing-related sales at $89 million, down from $176 million a year ago [6] - Worldwide Nutrition sales fell by 8.9% to $1.94 billion, attributed to lower sales volumes and strategic pricing actions [7] - Established Pharmaceuticals sales increased by 9% to $1.38 billion [7] Strategic Developments - In December 2025, the FDA approved Abbott's Volt PFA System for treating atrial fibrillation [5] - Abbott announced a $21 billion acquisition of Exact Sciences Corp, marking a significant deal in the healthcare sector [8] Guidance - The company anticipates organic sales growth of 6.5% to 7.5% for 2026 [10] Stock Performance - Abbott Laboratories shares fell by 7.37% to $111.63, reaching a new 52-week low [11]

Core Viewpoint - Abbott's quarterly earnings of $1.5 per share met the Zacks Consensus Estimate, showing an increase from $1.34 per share a year ago, with a slight earnings surprise of +0.20% [1] Financial Performance - Abbott reported revenues of $11.46 billion for the quarter ended December 2025, which was 2.76% below the Zacks Consensus Estimate and an increase from $10.97 billion year-over-year [2] - Over the last four quarters, Abbott has surpassed consensus EPS estimates three times but has only topped revenue estimates once [2] Stock Performance - Abbott shares have declined approximately 3.6% since the beginning of the year, contrasting with the S&P 500's gain of 0.4% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.19 on revenues of $11.17 billion, and for the current fiscal year, it is $5.67 on revenues of $48.01 billion [7] - The estimate revisions trend for Abbott was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Abbott belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8]